A US Drug Pricing Rebellion Looms, Analyst Says
Executive Summary
Wells Fargo analyst David Maris warned biopharma investors that the US drug market is on a long-term trajectory toward price controls, which he characterized as an under-appreciated risk for the sector, ahead of President Trump's speech on drug pricing.
You may also be interested in...
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments
There's a lot of finger-pointing in the industry when it comes to why pharma has a bad reputation. Maybe it's time everyone who works in pharmaceuticals takes responsibility for it.